News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
7,755 Results
Type
Article (1723)
Company Profile (2)
Press Release (6030)
Multimedia
Podcasts (13)
Webinars (1)
Section
Business (2424)
Career Advice (55)
Deals (513)
Drug Delivery (12)
Drug Development (1505)
Employer Resources (15)
FDA (274)
Job Trends (479)
News (4453)
Policy (494)
Tag
Academia (37)
Accelerated approval (1)
Adcomms (1)
Allergies (1)
Alliances (526)
ALS (4)
Alzheimer's disease (40)
Antibody-drug conjugate (ADC) (8)
Approvals (268)
Artificial intelligence (8)
Autoimmune disease (3)
Bankruptcy (2)
Best Places to Work (405)
BIOSECURE Act (1)
Biosimilars (41)
Biotechnology (1)
Brain cancer (1)
Cancer (82)
Cardiovascular disease (5)
Career advice (43)
Career pathing (1)
CAR-T (6)
Cell therapy (19)
Clinical research (1243)
Collaboration (30)
Complete response letters (2)
COVID-19 (51)
C-suite (12)
Cystic fibrosis (3)
Data (63)
Denatured (3)
Depression (8)
Diabetes (3)
Diagnostics (38)
Diversity, equity & inclusion (3)
Drug discovery (10)
Drug pricing (18)
Drug shortages (2)
Duchenne muscular dystrophy (2)
Earnings (876)
Editorial (5)
Employer branding (7)
Employer resources (12)
Events (1116)
Executive appointments (21)
FDA (307)
Funding (16)
Gene editing (2)
Gene therapy (14)
GLP-1 (43)
Government (124)
Guidances (5)
Healthcare (130)
Huntington's disease (4)
Immunology and inflammation (25)
Indications (2)
Infectious disease (55)
Inflammatory bowel disease (14)
Inflation Reduction Act (1)
Interviews (6)
IPO (220)
IRA (6)
Job creations (86)
Job search strategy (41)
Labor market (3)
Layoffs (24)
Legal (132)
Lung cancer (5)
Lymphoma (31)
Management (2)
Manufacturing (6)
MASH (1)
Medical device (37)
Medtech (37)
Mergers & acquisitions (309)
Metabolic disorders (19)
Multiple sclerosis (1)
Neurodegenerative disease (16)
Neuropsychiatric disorders (5)
Neuroscience (85)
NextGen: Class of 2025 (106)
Non-profit (39)
Now hiring (32)
Obesity (14)
Opinion (15)
Ovarian cancer (7)
Pain (2)
Parkinson's disease (15)
Partnered (1)
Patents (12)
Patient recruitment (1)
People (864)
Pharmaceutical (1)
Pharmacy benefit managers (4)
Phase I (371)
Phase II (479)
Phase III (662)
Pipeline (38)
Policy (17)
Postmarket research (24)
Preclinical (88)
Prostate cancer (1)
Psychedelics (3)
Radiopharmaceuticals (1)
Rare diseases (12)
Real estate (52)
Recruiting (8)
Regulatory (322)
Reports (1)
Research institute (43)
Resumes & cover letters (5)
RNA editing (2)
RSV (1)
Schizophrenia (22)
Series A (8)
Series B (3)
Special edition (2)
Startups (65)
Supply chain (1)
Tariffs (8)
The Weekly (9)
Vaccines (8)
Venture capital (8)
Weight loss (13)
Worklife (1)
Date
Today (5)
Last 7 days (9)
Last 30 days (30)
Last 365 days (572)
2025 (343)
2024 (708)
2023 (610)
2022 (1063)
2021 (915)
2020 (764)
2019 (681)
2018 (550)
2017 (526)
2016 (501)
2015 (553)
2014 (325)
2013 (184)
2012 (29)
2011 (3)
Location
Africa (25)
Arizona (1)
Asia (408)
Australia (46)
California (153)
Canada (22)
China (7)
Colorado (2)
Connecticut (5)
Delaware (1)
Europe (1263)
Florida (4)
Georgia (5)
Illinois (88)
India (2)
Indiana (7)
Iowa (1)
Japan (6)
Maryland (6)
Massachusetts (81)
Michigan (1)
Minnesota (2)
Missouri (1)
Nebraska (1)
New Hampshire (1)
New Jersey (27)
New York (17)
North Carolina (7)
Northern California (46)
Ohio (3)
Oregon (1)
Pennsylvania (16)
Rhode Island (1)
South America (27)
South Carolina (1)
Southern California (90)
Tennessee (6)
Texas (6)
United States (402)
Virginia (6)
Washington D.C. (3)
Washington State (3)
Wisconsin (2)
7,755 Results for "abbvie".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Lung Cancer
AbbVie’s ADC Nabs Accelerated Approval for Lung Cancer
AbbVie’s Emrelis is the first non-small cell lung cancer therapy approved for patients with high c-Met expression levels who have received prior lines of treatment.
May 15, 2025
·
2 min read
·
Tristan Manalac
Drug discovery
AbbVie Dives Further Into siRNA With $335M Upfront in ADARx Deal
The ADARx Pharmaceuticals partnership, which could be worth “several billion dollars” in the end, adds to AbbVie’s existing work in the space after the $1.4 billion acquisition of Aliada Therapeutics in October 2024.
May 14, 2025
·
2 min read
·
Annalee Armstrong
Cancer
AbbVie Scoops Up Ichnos Glenmark’s Lead Myeloma Antibody for Nearly $2B
The deal, which involves a $700 million upfront payment, gives AbbVie access to ISB 2001, a clinical-stage first-in-class trispecific antibody currently being tested for certain kinds of multiple myeloma as well as autoimmune indications.
July 10, 2025
·
1 min read
·
Dan Samorodnitsky
Mergers & acquisitions
AbbVie Plunks Down $2.1B for Capstan and Its Novel CAR T Therapies
The all-cash buyout, which gives AbbVie access to Capstan Therapeutics’
in vivo
edited CAR T therapy for B cell–mediated autoimmune diseases, adds to a growing sense of momentum in M&A, according to BMO Capital Markets.
June 30, 2025
·
2 min read
·
Dan Samorodnitsky
Earnings
AbbVie Criticizes Trump’s Drug Pricing Proposal, Deflects Tariff Concerns
While AbbVie handily beat expectations this quarter, the company faces declining Humira sales and a challenged aesthetics business, plus the same macro headwinds blowing against the entire industry.
April 25, 2025
·
3 min read
·
Annalee Armstrong
Earnings
AbbVie’s Marketing Misstep Further Erodes 2024 Aesthetics Sales
AbbVie launched a revamped version of its Allē loyalty program, which ultimately was not adopted by providers. The marketing misstep comes as the company’s aesthetics franchise faces broader pressures.
February 3, 2025
·
4 min read
·
Annalee Armstrong
Earnings
AbbVie Pats Own Back as Skyrizi and Rinvoq Rake in Billions
Move over Humira, Skyrizi and Rinvoq are expected to beat the former megablockbuster’s peak sales by the end of this year.
July 31, 2025
·
2 min read
·
Dan Samorodnitsky
Cancer
Roche, AbbVie’s Venclexta Stumbles Again, This Time in Myelodysplastic Syndromes
Venclexta, when combined with azacitidine, elicited an overall survival benefit below 10% in patients with myelodysplastic syndromes.
June 17, 2025
·
1 min read
·
Tristan Manalac
Legal
AbbVie Lawsuit Alleges That Partner Genmab “Misappropriated” Trade Secrets
AbbVie claims that Genmab turned a blind eye to trade secret theft allegedly used to support the development of ProfoundBio’s investigational antibody-drug conjugates. Genmab acquired ProfoundBio in May 2024.
March 24, 2025
·
2 min read
·
Tristan Manalac
Immunology and inflammation
AbbVie Carves Out Niche for Rinvoq With ‘Impressive’ Alopecia Areata Data
Rinvoq’s efficacy in alopecia areata is “impressive,” according to Guggenheim analysts, who said the drug could have a competitive edge over other JAK inhibitors in the space.
July 31, 2025
·
2 min read
·
Tristan Manalac
1 of 776
Next
